Path to Market Strategy From early phase, to patients

Designing and evaluating alternative paths to approval, reimbursement and commercial success.

From early phase, to patients

Path-to-Market strategy is about options: choices for how to take a molecule to market, optimising for clinical, regulatory and commercial hurdles.

You need a way to generate path to market choices, and a way to decide between them. That's where we come in.

There is a window of opportunity to differentiate by design

Delivering our Path to Market service.

The methodology, the discipline of making choices about Path to Market.

1 Deep insight on the talents of your molecule, creativity to challenge the 'obvious'

2 Create a longlist of differentiating path to market ideas

3 Methodology to generate a robust shortlist

4 Conduct external pressure testing of the choices

5 Decisioning

Path to market insights and innovation.

You can't develop tomorrow's medicines with yesterday's thinking.

From the blog
See all

2024 Pharmaceutical Innovation Index top 10

2024 Pharmaceutical Innovation Index top 10

Read article
Latest podcast
See all

IDEA Podcast with Mike Rea